Literature DB >> 18542927

Receptor-independent sensitization of the adenylyl cylase after chronic treatment with cyclosporine A.

G Simonis1, T Christ, S K Bährle, M Pena, S P Schoen, R Marquetant, U Ravens, R H Strasser.   

Abstract

Chronic treatment with cyclosporine A (CyA) is often complicated by severe hypertension. If activation of the beta-adrenergic-receptor-linked adenylyl cyclase (AC) system contributes to hypertension is unresolved. Rats were treated with CyA (20 mg kg(-1) day(-1)) for 7 days. beta-adrenergic, muscarinic, and alpha-adrenergic receptors, G-proteins, and the activity of AC were determined in cardiac and pulmonary plasma membranes. The density of cardiac beta-adrenergic receptors, muscarinic receptors, alpha-adrenergic receptors, G(alphas) and, G(alphai) remained unchanged after treatment with CyA. However, CyA increased the responsiveness of AC to different stimulators. The responsiveness of AC was even more pronounced after solubilization and partial purification, suggesting a direct modulation of the enzyme. These data suggest that CyA modulates the activity of the sympathoadrenergic system by a direct, receptor-independent sensitization of AC, suggesting that this pathway contributes to hypertension in patients treated with CyA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18542927     DOI: 10.1007/s00210-008-0319-2

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine.

Authors:  K H Jakobs; W Saur; G Schultz
Journal:  J Cyclic Nucleotide Res       Date:  1976 Nov-Dec

2.  Alpha 1-receptor-independent activation of protein kinase C in acute myocardial ischemia. Mechanisms for sensitization of the adenylyl cyclase system.

Authors:  R H Strasser; R Braun-Dullaeus; H Walendzik; R Marquetant
Journal:  Circ Res       Date:  1992-06       Impact factor: 17.367

3.  Inhibition of T cell cAMP formation by cyclosporin A and FK506.

Authors:  H M Ockenfels; S N Wagner; P Oeljeklaus; B Schneck; G Nussbaum; K H Jakobs; M Goos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Changes in cAMP formation in mononuclear leukocytes of heart and renal transplant recipients.

Authors:  H Lensche; F Diet; W von Scheidt; P Uberfuhr; B Reichart; E Erdmann; M Böhm
Journal:  Res Exp Med (Berl)       Date:  1994

7.  Translocation and uncoupling of the beta-adrenergic receptor in rat lung after catecholamine promoted desensitization in vivo.

Authors:  R H Strasser; G L Stiles; R J Lefkowitz
Journal:  Endocrinology       Date:  1984-10       Impact factor: 4.736

8.  Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion.

Authors:  J P Raufman; J Lin; R D Raffaniello
Journal:  J Biol Chem       Date:  1996-08-16       Impact factor: 5.157

9.  Cyclosporine attenuates the adenylyl cyclase superactivation induced by chronic cannabinoid treatment.

Authors:  Hamid R Banafshe; Mahmoud Ghazi-Khansari; Shahram Ejtemaei Mehr; Ahmad R Dehpour
Journal:  Eur J Pharmacol       Date:  2006-11-14       Impact factor: 4.432

Review 10.  Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction.

Authors:  Steven A Baroletti; Steven Gabardi; Colm C Magee; Edgar L Milford
Journal:  Pharmacotherapy       Date:  2003-06       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.